Pharmaceutical and biotechnology companies continuously develop new drugs to address the ever-changing medical landscape and health threats.

However, many of the new drugs developed suffer from toxicity concerns or limited systemic administration bio-availability that impede on their safety and efficacy.

Additionally, companies are looking for ways to extend exclusivity of their proprietary products, in particular for drugs in their portfolio that approach patent expiration.

PolyPid’s proprietary platform, PLEX™ (Polymer-Lipid Encapsulation matriX), is a protective drug encapsulation platform that allows a controlled, local release rate over extended periods of time (up to months).

We have proved the versatility of our platform with pre-clinical trials and in some cases even clinical trials, using small molecules, peptides and proteins.

Partnering with us will provide companies a targeted, local drug delivery vehicle that will optimize their drugs’ therapeutic payload and clinical outcome, and where applicable, help overcome a looming patent cliff.

We always welcome collaborations that will help patients, so we invite you to direct all partnership inquiries to BD@polypid.com

Strategic Partners
MIS Implants Technologies
PolyPid entered into a commercial understanding with MIS Dental Implants Ltd. (MIS), a leading manufacturer of dental implants, recently acquired by DENTSPLY-SIRONA. This covers the development, distribution and sale of BonyPid-500™ for the indication of peri-implantitis.
Development Partners
Biofilm Alliance – BALI
BALI is developing a unique treatment of biofilm-associated infections. The new treatment will be based on a combination of two highly innovative technologies: Synthetic Antibacterial Anti-biofilm Peptides (SAAP), and PLEX™ platform technology for the controlled and prolonged release of any Active Pharmaceutical Ingredient (API). The project is funded by the European Union’s Seventh Framework Program. The consortium comprises European universities and companies.
Rimonim
The consortium was established to promote siRNA-based therapeutics. It is focused on the chemistry and delivery of RNA-based drugs for cancer treatment and comprised of Israeli biotechnology companies and major universities under the Israeli Government’s Office of the Chief Scientist.

Technology

The PLEX™ (Polymer-Lipid Encapsulation matriX) platform is a matrix made of alternating layers of polymers and lipids that allows controlled, local release of unmodified drugs over extended periods of time.

Read More >

D-PLEX™

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >

BonyPid-1000™

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >